Weekly reads: 1st FDA-approved CIRM supported therapy, asymmetric histone inheritance, stem cell retraction – The Niche

Date:

Node: 4973717

We recently saw exciting news with the first CIRM-funded therapy garnering FDA approval.

Before we jump into that and other news and new publications, a reminder that my lab is still crowdfunding to support our brain tumor research in these tough funding times. Please consider making a tax-deductible gift to give more hope for kids and adults facing brain tumors. Thanks!

CIRM
CIRM funded research is having impact including in the clinic.

CIRM-funded therapy gets FDA approval

The approved therapy supported by CIRM funding is KRESLADI from Rocket Pharmaceuticals, Inc. It will be used to treat a condition called severe leukocyte adhesion deficiency-I (LAD-I) in children who have no bone marrow donor match for stem cell transplantation.

This is a great milestone for CIRM and I expect more drug approvals related to CIRM-funded research.

Educational videos

There are two reasons I’ve been writing more about peptides in the last few years. First, people are getting hurt by these peptides and more are at risk. Second, the peptides are often claimed to have regenerative medicine-type properties. Stem cell communicator and student Parmin Sedigh and I have a new, growing series of educational videos. The newest video is just a few minutes on peptides as to key things to know.

If you like it, please follow the YouTube channel.

[embedded content]

More recommended reads

#mp_form_below_posts4 .mailpoet_form { }
#mp_form_below_posts4 .mailpoet_column_with_background { padding: 10px; }
#mp_form_below_posts4 .mailpoet_form_column:not(:first-child) { margin-left: 20px; }
#mp_form_below_posts4 .mailpoet_paragraph { line-height: 20px; margin-bottom: 20px; }
#mp_form_below_posts4 .mailpoet_segment_label, #mp_form_below_posts4 .mailpoet_text_label, #mp_form_below_posts4 .mailpoet_textarea_label, #mp_form_below_posts4 .mailpoet_select_label, #mp_form_below_posts4 .mailpoet_radio_label, #mp_form_below_posts4 .mailpoet_checkbox_label, #mp_form_below_posts4 .mailpoet_list_label, #mp_form_below_posts4 .mailpoet_date_label { display: block; font-weight: normal; }
#mp_form_below_posts4 .mailpoet_text, #mp_form_below_posts4 .mailpoet_textarea, #mp_form_below_posts4 .mailpoet_select, #mp_form_below_posts4 .mailpoet_date_month, #mp_form_below_posts4 .mailpoet_date_day, #mp_form_below_posts4 .mailpoet_date_year, #mp_form_below_posts4 .mailpoet_date { display: block; }
#mp_form_below_posts4 .mailpoet_text, #mp_form_below_posts4 .mailpoet_textarea { width: 200px; }
#mp_form_below_posts4 .mailpoet_checkbox { }
#mp_form_below_posts4 .mailpoet_submit { }
#mp_form_below_posts4 .mailpoet_divider { }
#mp_form_below_posts4 .mailpoet_message { }
#mp_form_below_posts4 .mailpoet_form_loading { width: 30px; text-align: center; line-height: normal; }
#mp_form_below_posts4 .mailpoet_form_loading > span { width: 5px; height: 5px; background-color: #5b5b5b; }#mp_form_below_posts4{border: 0px solid #ffffff;border-radius: 0px;background: #edf3f8;text-align: left;}#mp_form_below_posts4 form.mailpoet_form {padding: 20px;}#mp_form_below_posts4{width: 100%;}#mp_form_below_posts4 .mailpoet_message {margin: 0; padding: 0 20px;}#mp_form_below_posts4 .mailpoet_paragraph.last {margin-bottom: 0} @media (max-width: 500px) {#mp_form_below_posts4 {background: #edf3f8;}} @media (min-width: 500px) {#mp_form_below_posts4 .last .mailpoet_paragraph:last-child {margin-bottom: 0}} @media (max-width: 500px) {#mp_form_below_posts4 .mailpoet_form_column:last-child .mailpoet_paragraph:last-child {margin-bottom: 0}}

#mp_form_popup5 .mailpoet_form { }
#mp_form_popup5 .mailpoet_column_with_background { padding: 10px; }
#mp_form_popup5 .mailpoet_form_column:not(:first-child) { margin-left: 20px; }
#mp_form_popup5 .mailpoet_paragraph { line-height: 20px; margin-bottom: 20px; }
#mp_form_popup5 .mailpoet_segment_label, #mp_form_popup5 .mailpoet_text_label, #mp_form_popup5 .mailpoet_textarea_label, #mp_form_popup5 .mailpoet_select_label, #mp_form_popup5 .mailpoet_radio_label, #mp_form_popup5 .mailpoet_checkbox_label, #mp_form_popup5 .mailpoet_list_label, #mp_form_popup5 .mailpoet_date_label { display: block; font-weight: normal; }
#mp_form_popup5 .mailpoet_text, #mp_form_popup5 .mailpoet_textarea, #mp_form_popup5 .mailpoet_select, #mp_form_popup5 .mailpoet_date_month, #mp_form_popup5 .mailpoet_date_day, #mp_form_popup5 .mailpoet_date_year, #mp_form_popup5 .mailpoet_date { display: block; }
#mp_form_popup5 .mailpoet_text, #mp_form_popup5 .mailpoet_textarea { width: 200px; }
#mp_form_popup5 .mailpoet_checkbox { }
#mp_form_popup5 .mailpoet_submit { }
#mp_form_popup5 .mailpoet_divider { }
#mp_form_popup5 .mailpoet_message { }
#mp_form_popup5 .mailpoet_form_loading { width: 30px; text-align: center; line-height: normal; }
#mp_form_popup5 .mailpoet_form_loading > span { width: 5px; height: 5px; background-color: #5b5b5b; }#mp_form_popup5{border: 0px solid #ffffff;border-radius: 0px;background: #edf3f8;text-align: left;}#mp_form_popup5{width: 560px;max-width: 100vw;}#mp_form_popup5 .mailpoet_message {margin: 0; padding: 0 20px;}#mp_form_popup5 .mailpoet_paragraph.last {margin-bottom: 0} @media (max-width: 500px) {#mp_form_popup5 {background: #edf3f8;animation: none;border: none;border-radius: 0;bottom: 0;left: 0;max-height: 40%;padding: 20px;right: 0;top: auto;transform: none;width: 100%;min-width: 100%;}} @media (min-width: 500px) {#mp_form_popup5 {padding: 20px;}} @media (min-width: 500px) {#mp_form_popup5 .last .mailpoet_paragraph:last-child {margin-bottom: 0}} @media (max-width: 500px) {#mp_form_popup5 .mailpoet_form_column:last-child .mailpoet_paragraph:last-child {margin-bottom: 0}}